Press releases

Press release2020/05/26

Medivir appoints Yilmaz Mahshid as new CEO

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR) today announced that its Board of Directors has appointed Yilmaz Mahshid as the new...

Press release2020/05/06

FDA grants MIV-818 Orphan Drug Designation for the treatment of hepatocellular carcinoma

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan...

Press release2020/05/05

Resolutions at the Annual General Meeting in Medivir on 5 May 2020

Approval of profit and loss accounts and balance sheets, and discharge from liability of the board members and the managing director...

Press release2020/05/05

MEDIVIR AB – INTERIM REPORT JANUARY – MARCH 2020

January – March Significant events during the quarter Data from the phase Ia study with MIV-818 in liver cancer patients presented...

Press release2020/04/30

Medivir receives positive opinion on Orphan Medicinal Drug Designation by the European Medicines Agency for MIV-818

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that it has received positive opinion from the Committee for Orphan...

Press release2020/04/15

Medivir announces departure of Chief Medical Officer

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces that Linda Basse, Chief Medical Officer at Medivir will leave the company...

Press release2020/04/06

Medivir 2019 Annual Report published

Stockholm, Sweden - Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2019 now is available at the...

Press release2020/04/06

Notice of Annual General Meeting of Medivir AB (publ)

The shareholders of Medivir AB are hereby summoned to the annual general meeting on Tuesday 5 May 2020 at 2 p.m....

Press release2020/03/16

Medivir and Tango Therapeutics sign license agreement for preclinical asset

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that it has entered into a license agreement with US biotech...

Press release2020/03/10

First liver cancer patient dosed in the MIV-818 phase Ib study

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that the first patient with advanced liver cancer has been dosed...

Press release2020/03/02

Medivir presents positive data from the completed phase Ia study with MIV-818 in patients with advanced liver cancer

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces that new data from the completed phase Ia study with MIV-818 will...

Press release2020/02/25

Invitation to Medivir's R&D Day on March 2, 2020

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) invites investors, analysts and the media to a R&D Day in Stockholm, Monday...